Fordadistrogene movaparvovec ( DrugBank: Fordadistrogene movaparvovec )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
113	Muscular dystrophy	2

113. Muscular dystrophy

---

Clinical trials : 646 /  Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05689164 (ClinicalTrials.gov)	April 14, 2023	9/1/2023	A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.	Long-term Follow-up Safety and Efficacy Study in Participants With Duchenne Muscular Dystrophy Who Have Received Fordadistrogene Movaparvovec in a Preceding Clinical Study	Duchenne Muscular Dystrophy	Biological: fordadistrogene movaparvovec	Pfizer	NULL	Not yet recruiting	0 Years	N/A	Male	250	Phase 3	NULL
2	NCT05429372 (ClinicalTrials.gov)	August 8, 2022	8/10/2021	Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy	A PHASE 2, MULTICENTER, SINGLE-ARM STUDY TO EVALUATE THE SAFETY AND DYSTROPHIN EXPRESSION AFTER FORDADISTROGENE MOVAPARVOVEC (PF-06939926) ADMINISTRATION IN MALE PARTICIPANTS WITH EARLY STAGE DUCHENNE MUSCULAR DYSTROPHY	Muscular Dystrophy, Duchenne	Genetic: PF-06939926	Pfizer	NULL	Recruiting	2 Years	3 Years	Male	10	Phase 2	United States;Australia